medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1

2

Waning of post-vaccination neutralizing antibody responses against SARS-CoV-2, a systematic literature review and meta-analysis

- 3 Henning Jacobsen^{1*}, Ioannis Sitaras², Maeva Katzmarzyk³, Viviana Cobos Jiménez³, Robert 4 Naughton³, Melissa M. Higdon⁴, and Maria Deloria Knoll⁴
- 5 ¹Department of Viral Immunology, Helmholtz Center for Infection Research, Braunschweig,
- 6 Germany
- 7 ²W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins
- Bloomberg School of Public Health, Baltimore, MD, United States 8
- ³Independent consultant 9
- ⁴International Vaccine Access Center, Department of International Health, Johns Hopkins 10 Bloomberg School of Public Health, Baltimore, MD, United States 11
- *Correspondence: henning.jacobsen@helmholtz-hzi.de 12
- 13

14 Summary

Background 15

- 16 Mass COVID-19 vaccination and the continuous introduction of new viral variants of SARS-
- CoV-2, especially of Omicron subvariants, has resulted in an increase in the proportion of the 17
- population with hybrid immunity at various stages of waning protection. We systematically 18
- reviewed waning of post-vaccination neutralizing antibody titers in different immunological 19
- settings to investigate potential differences. 20

21 Methods

22 We searched for studies providing data for post-vaccination neutralizing antibody responses against SARS-CoV-2 in PubMed, bioRxiv, and medRxiv from Dec 15, 2021, to Jan 31, 2023, 23 24 using keywords related to COVID-19, vaccination, and antibody neutralization. We used random effects meta-regression to estimate the average fold-reduction in post-vaccination 25 neutralizing antibody titers against the Index strain or Omicron BA.1. from month 1 to month 26 6 post last dose, stratified by vaccination regimen (primary or booster) and infection-naïve vs 27 hybrid-immune status. 28

29 Findings

In total, 26 studies reporting longitudinal post-vaccination neutralizing antibody titers were 30 31 included. Neutralization titers against the Index variant were available from all studies for 32 infection-naïve participants, and from nine for hybrid-immune participants. Against Omicron BA.1, nine and eight studies were available for infection-naïve and hybrid-immune cohorts, 33 respectively. In infection-naïve cohorts, post-vaccination neutralization titers against the 34 Index strain waned 5.1-fold (95% CI 3.4-7.8) from month 1 to month 6 following primary 35 regimen and 3.8-fold (95% CI 2.4-5.9) following the booster. Titers against Omicron BA.1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 36 waned 5.9-fold (95% CI 3.8-9.0) in infection-naïve, post-booster cohorts. In hybrid-immune, 37

medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

post-primary vaccination cohorts, titers waned 3.7-fold (95% CI 1.7-7.9) against the Index
 strain and 5.0-fold (95% CI 1.1-21.8) against Omicron BA.1.

40

41 Interpretation (250 words)

No obvious differences in waning between post-primary or post-boost vaccination were observed for vaccines used widely to date, nor between infection-naïve and hybrid-immune participants. Titers against Omicron BA.1 may wane faster compared to Index titers, which may worsen for more recent Omicron sub-variants and should be monitored. Relatively small datasets limit the precision of our current analysis; further investigation is needed when more data become available. However, based on our current findings, striking differences in waning for the analyzed and future comparisons are unlikely.

49

50 Introduction

COVID-19 vaccines continue to effectively protect against severe disease and death caused by 51 SARS-CoV-2 despite continuous viral evolution and waning immunity¹⁻³. However, vaccine 52 effectiveness against SARS-CoV-2 transmission, infection, and symptomatic disease has 53 declined, and immunity against the Wuhan Index strain, either elicited by vaccination or 54 previous infection, shows little protection against infection with Omicron-related viral 55 variants^{2–4}. Thus hybrid immunity (immunity developed through a combination of SARS-CoV-56 57 2 infection and vaccination) involving infections with more recent viral variants is increasingly relevant. Clinical studies are imperative for assessing the impact of novel viral variants on 58 59 vaccine performance and understanding the waning of protection after vaccination and/or 60 infection, but these studies demand significant time. While laboratory data, such as neutralizing antibody titers, can be generated and shared much more quickly thereby 61 62 potentially informing vaccine policy when clinical data are lacking, single studies often lack the power to provide sound and robust conclusions regarding complex biological functions such 63 as antibody waning⁵. Meta-analysis of data across studies can increase power and can 64 evaluate impact of different immunological factors, including number of doses and effects of 65 66 hybrid immunity.

We systematically reviewed the evidence of post-vaccination neutralization antibody titers against the Index strain and Omicron BA.1 over time and compared the degree of waning after the last dose between primary and booster vaccination and between infection-naïve and hybrid-immune participants.

- 71
- 72
- 73
- , ,
- 74
- 75

medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

76 Methods

77 Search strategy and selection criteria

The systematic review and meta-regression were conducted according to the Preferred
 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

We searched PubMed, medRxiv, and bioRxiv from December 15, 2021, to January 31, 2023, using the keywords "COVID-19", "Omicron", and "neutralization". Two reviewers (HJ, IS) screened titles and abstracts and conducted full-text review; inclusion was limited to studies providing neutralization data against both the Index (Wuhan-line) strain and Omicron BA.1.

To investigate systematically if booster doses (compared to primary series) or hybrid immunity 84 85 (compared to infection naïve) affect the rate of neutralizing antibody waning, we performed meta-regressions assessing change in neutralization titers over time for strata with six or more 86 87 cohorts. We included studies reporting post-vaccination neutralizing antibody titers (using 88 authentic virus or pseudo-virus neutralization assays) for at least two time-points following 89 last vaccine dose. In the case of pseudo-virus neutralization assays, we included only studies where the pseudo-viruses used carried the complete complement of spike mutations 90 characteristic of the variant they represented. Data resulting from surrogate neutralization 91 92 titers were not assessed. Per study, all cohorts were assessed that matched the inclusion criteria and, therefore, one study could contribute multiple observations from different 93 cohorts. We collected outcomes from studies investigating infection-naïve cohorts post-94 95 primary or post first booster vaccination, and from hybrid-immune cohorts, post-primary 96 vaccination. Studies were excluded if they did not provide neutralization titers against the 97 Index strain and Omicron BA.1, did not provide neutralization data for at least two time points, 98 if cohort characteristics did not match the scope of the analysis (assessment of non-licensed vaccines, immunocompromised participants) or if information regarding previous infection 99 100 history of the study cohort was insufficient. We excluded studies evaluating infection-naïve, 101 post-primary vaccination titers against Omicron BA.1 because of overall low or undetectable 102 titers^{6,7}. Geometric mean titers (GMT) against the Index strain and Omicron BA.1 as measured 103 by authentic virus neutralization assays or pseudo-virus-based neutralization assays were abstracted. 104

105

106 Assessment of study reliability

We systematically assessed the reliability of included studies using a tool we previously developed tailored for studies reporting post-vaccination neutralizing antibody responses⁵. The tool assesses reporting quality (e.g., methodological detail, description of relevant clinical data, etc.), overall strength of the data, and standardization measures using a standardized set of criteria and metrics. Each aspect is rated with an output (no, low, medium, high, or unclear risk of unreliability), resulting in an overall score for each study.

113

114 Analysis

medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Average declines in GMTs were estimated stratified by dose (primary, first booster), prior infection status (naïve vs hybrid-immune), and strain (Index vs. Omicron BA.1). Primary vaccination was defined as one dose of Ad26.CoV2.S vaccine or two doses of any other included vaccine. Booster vaccination was defined as one dose of any COVID-19 vaccine after any primary series vaccination. Hybrid-immune cohorts included convalescent participants who had an infection prior to the last dose.

The natural log of neutralization antibody response GMT (logGMT) was calculated for all available time points post final dose. If not provided, GMT was calculated using raw data when available or abstracted from high-resolution figures. If the standard deviation (SD) corresponding to each logGMT was not provided, it was derived from confidence intervals (CIs); if no CIs were provided, within each of the five comparison groups, SD was imputed by calculating the median SD among other observations with SDs reported.

The average change in logGMT was estimated using a linear mixed effects model for the 127 128 repeated measures within each comparison group (PROC MIXED; SAS 9.4). The standard errors calculated from SDs, and sample sizes abstracted from the studies were squared to produce 129 estimates of residual variances for inverse weighting in the linear mixed effects model. The 130 logGMT was regressed on months since vaccination; we evaluated non-linearity by including 131 132 a quadratic term for time, which was not statistically significant in any model (all p > .15). Models were adjusted for vaccine platform. Difference in degree of waning by dose, prior 133 infection status, strain, or vaccine platform was assessed using an interaction term with time 134 in models, adjusting for other covariates. Confidence interval bands for average logGMT over 135 136 time in plots were estimated by re-defining the intercept in the model by centering the time 137 variable monthly from 1 to 6 months. Results are presented as GMTs by exponentiating model 138 outputs. Statistical significance was defined as p < .05; adjustments for multiple comparisons were not made. 139

140

141 <u>Results</u>

We screened titles and abstracts from 8418 articles, of which 347 underwent full-text review and 26 were eligible for analyses (Figure 1). Abstracted neutralization titers and relevant cohort characteristics including study population, number of doses, vaccine product, and infecting strain are provided in Supplementary appendix 1.


Five strata had six or more cohorts for meta-analyses: 1) infection-naïve, post-primary 146 147 vaccination titers against the Index strain (n= 18 cohorts); 2) infection-naïve, post-boost 148 vaccination titers against the Index strain (n= 18); 3) infection-naïve, post-boost vaccination titers against Omicron BA.1 (n= 15); 4) hybrid-immune, post-primary vaccination against the 149 150 Index strain (n= 8); and 5) hybrid-immune, post-primary vaccination against Omicron BA.1 (n= 6; Figure 1). Too few (\leq 3 cohorts) assessed hybrid-immune, post-booster vaccination 151 152 titers, vaccination with four or more doses, or vaccination with variant-adapted vaccines, and 153 were therefore not meta-analyzed. Among hybrid-immune cohorts, all studies evaluated infections occurring prior to the last dose except one, which provided data after breakthrough 154 155 infection but was excluded from meta-analysis because sampling time-points were unclear⁸].

medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

156 All hybrid-immunity cohorts were from pre-Omicron infections so we could not assess impact

157 of variant-specific effects on hybrid-immunity.



158

159 Figure 1: Study identification and Selection.

There was wide heterogeneity in peak GMTs across studies within strata, for example ranging 160 between 101 and 4096 among infection-naïve participants boosted with mRNA vaccines 161 162 (Figure 2b, supplementary appendix 1), resulting in wide confidence intervals of metaanalyses. Average peak GMTs differed between strata, with highest average GMTs observed 163 against the Index strain in hybrid-immune post-primary participants and lowest against 164 165 Omicron BA.1 in infection-naïve post-boost participants (Table 1, Figure 2). As expected, average peak titers post-vaccination were higher in subjects with an infection history 166 compared to naïve subjects and titers against Omicron BA.1 were generally lower than those 167 against the Index strain. Mean peak titers were significantly higher for mRNA vaccines 168 compared to other vaccine platforms; however, few studies evaluated inactivated (n=3 169 cohorts from 3 studies^{9–11}) or viral vector vaccines (n= 8 cohorts from 6 studies^{12–17}), and only 170 two of these studies provide direct comparisons to other platforms^{12,13}. 171

Average neutralization titers declined from month 1 to 6 in all five strata, ranging from 3.7-172 fold (95%CI 1.7-7.9) against the Index strain in hybrid-immune participants post-primary to 173 5.9 (95% CI 3.8-9.0) against Omicron BA.1 in infection-naïve boosted participants (Table 1, 174 Figure 2), but the declines were not statistically significantly different between strata (p= .67). 175 The rate of waning in the first 6 months appeared linear in all five strata (all p > 0.15 for 176 quadratic term), but most cohorts (39 of 48; 81.2%) provided data for only two time-points 177 and no eligible studies had more than three time-points. Although declines in neutralizing 178 179 antibodies cross-reactive to Omicron BA.1 appeared to be greater than declines of Index-180 specific responses in both infection-naïve and hybrid-immune cohorts (5.0- to 5.9-fold reductions vs. 3.7- to 3.8-fold, respectively), they were not statistically significant (p= .22), nor 181 were rates of decline statistically different for any covariate evaluated (all p > .17). 182


medRxiv preprint doi: https://doi.org/10.1101/2023.08.08.23293864; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

183 Neutralization titers declined in all cohorts except two (Figure 2 panel B), that were from a single study¹² that assessed titers at shorter follow-up times (months 1 and 3), among 184 participants vaccinated with a vector vaccine (of five comparable cohorts that evaluated 185 vector vaccines). Statistically significant increases in neutralizing antibody (GMTs from 1090.5 186 to 1444.3) against the Index strain were observed in one cohort that received a heterologous 187 188 booster with Ad26.CoV2.S as a third dose after two doses of mRNA vaccine in infection-naïve participants. There was no change in a second cohort that received two doses of Ad26.CoV2.S 189 (GMTs 122.8 and 138.2); however, titers against Omicron BA.1 declined in both (358.9 to 190 123.0 and 26.9 to 11.2, respectively; both p < .05) and significant declines were observed for 191 192 two other cohorts in the same study that received either mRNA vaccines or heterologous 193 vaccination with Ad26.CoV2.S as a first dose.

195 Table 1: Average peak and 5-month waning of neutralizing antibody titers in infection-naïve and hybrid-immune 196 cohorts against the Index strain and Omicron BA.1

Infection status	Dose	Strain	Group	Group size (studies/cohorts/ Participants)	Average Peak GMT (95% CI)	mRNA cohorts [%]	Average fold decline in GMT, 1-6 months (95% CI)
	Prime	Index	А	16/19/438	718.0 (384.0-1341.0)	61.1	5.1 (3.4-7.8)
Infection naïve		Index	В	13/21/620	954.0 (466.0-1951.0)	50.0	3.8 (2.4-5.9)
	Boost	Omicron BA.1	D	10/16/584	169.0 (76.0-377.0)	53.3	5.9 (3.8-9.0)
Hybrid- immune	Prime	Index C		7/8/143	2803.0 (1651.0-4760.0)	62.5	3.7 (1.7-7.9)
	Prine	Omicron BA.1	E	6/6/93	339.0 (193.0-595.0)	50.0	5.0 (1.1-21.8)

197



199 Figure 2: Neutralizing antibody titers over time since last vaccination against the Index strain or Omicron BA.1 in 200 infection-naïve or hybrid-immune participants after primary or booster vaccination. Rates of waning against the 201 Index strain (A - C) and against Omicron BA.1 (D and E) are shown stratified by prior infection status and dose. Lines 202 connecting data points represent individual cohorts, color coded by vaccine platform. Bold red lines represent 203 average declines from meta-regression for each stratum; shaded area represents 95% confidence intervals of GMT 204 over time. Abbreviations: GMT, geometric mean titer; CI, confidence interval; Index, SARS-CoV-2 Wuhan-like 205 including D614G-strains; +mRNA, heterologous vaccine regimen involving at least one mRNA-vaccine dose; -mRNA, 206 heterologous vaccine regimen involving no mRNA-vaccine dose.

207 Assessment of study reliability

208 Assessment of reliability of the 26 eligible studies classified only four studies (15.4%) as having 209 high reliability; four (15.4%) had medium reliability, six (23.1%) had low reliability, and 14 (53.9%) 210 had unclear reliability because critical information was not provided (Supplementary Figure 1). Unclear or low-reliability scores were primarily attributable to poor reporting quality (e.g., input 211 titer used, spike complement, etc.) regarding pseudo-virus constructs (seven studies, 26.9%) or 212 213 assay standardization (12 studies, 46.2%; Supplementary Figure 1). Analyses stratified by 214 reliability score showed that neither peak titers nor waning rates differed markedly between 215 studies with medium to high reliability scores compared to low reliability (Supplementary Figure 216 2). Individual scoring results are provided as Supplementary Appendix 2.

217

218 Discussion

Through a systematic literature review and meta-analysis, we found neutralizing antibodies 219 declined after COVID-19 vaccination from months one to six ranging from 3.7-fold to 5.9-fold 220 221 when evaluating post-primary or first booster against either the Index strain or Omicron BA.1. 222 Waning rates were generally similar after primary or first booster regimens, and between infection-naïve and previously infected cohorts. Declines of neutralizing antibodies cross-reactive 223 to Omicron BA.1 were greater than declines of Index-specific responses, both in infection-naïve 224 225 and hybrid-immune cohorts, though this difference was not statistically significant. Only three studies evaluated a second booster; two reported no significant differences in waning kinetics 226 between first and second booster^{26,27} and one reported slightly enhanced antibody durability 227 after the second booster, but the second booster cohort was small (n=7)²¹. Because waning was 228 229 similar after primary and first booster doses, degree of waning with subsequent doses is also expected to be similar. However, data to assess long-term waning, such as 12 months after the 230 231 last vaccine dose, were unavailable, complicated both by needing to wait that long and by study subjects getting revaccinated before that time. As duration between vaccinations increases, this 232 may be addressed in future studies. These waning rates could be used to predict waning for 233 future relevant scenarios and adapt vaccination strategies accordingly. 234

235 Declines in neutralization titers were observed in all but three infection-naïve cohorts evaluated. One cohort that received a heterologous boost regimen (inactivated prime followed by a vector 236 boost) was followed for 3 months and no change in titers was observed⁹. However, overall titers 237 were low throughout. Two additional cohorts, one vaccinated with two doses of vector vaccine 238 239 (out of five available vector-immunized cohorts) and one with a heterologous regimen (mRNA prime followed by a vector boost) had titers that increased against the Index strain through 240 month 3 (longer follow-up was not conducted)¹². Titers against Omicron BA.1 declined in these 241 cohorts indicating that no undetected breakthrough infection occurred driving these titer 242 increases. Interestingly, these three exceptional cohorts all received a vector vaccine as the last 243 244 dose and hence it can be speculated that vector-mediated immunization might cause more

245 durable antibody responses early after immunization/booster. On the other hand, studies with longer-term follow-up support overall comparable rates of waning across vaccine platforms 246 247 beyond three months after the last dose, which might be explained by full clearance of the vector and any benefit it might add. More studies are needed to address this important observation and 248 249 explore the potential role vector vaccines could play in enhancing durable immune responses. 250 While we and others have shown that vector vaccines are generally less immunogenic compared 251 to mRNA vaccines, heterologous regimens combining mRNA and vector vaccines have been shown to elicit immune responses comparable to mRNA vaccinations alone^{13,29}. Hence, boosters 252 253 with vector vaccines in mRNA-primed (or already mRNA-boosted) participants could elicit the highest and most durable immune responses. This has been shown by Lyke et al. who observed 254 255 that titers were more stable in subjects who received an mRNA prime followed by a vector boost than subjects who received three doses of mRNA vaccine¹². We identified four additional cohorts 256 257 (from three studies) evaluating hybrid-immune subjects that did not show a significant decline of 258 titers in the observed period, and two of these cohorts were followed for more than six months post-last vaccine dose^{8,16,30}. However, two of the studies did not investigate breakthrough 259 infections after the last vaccine dose^{8,30}. Breakthrough infections in even a small proportion of 260 the subjects can have a large impact on the overall GMT because the impact of these few 261 262 infections on the overall GMT of a group can be large. Therefore, these studies should be 263 considered with caution. Still, one study on hybrid-immune subjects that ruled out breakthrough infections after the last vaccine dose showed stable titers over a three-month period¹⁶ which 264 supports other observations that hybrid-immunity might have the potential to stabilize antibody 265 266 titers at least temporarily²¹.

267 Neutralizing antibody titers can support and complement clinical vaccine effectiveness data as they correlate well with protection against infection and mild disease. Even if neutralizing 268 antibodies fail to hinder initial infection and symptomatic disease, they will limit initial viral load 269 270 and thus mitigate disease progression, so they correlate also with protection against severe 271 disease. This can be seen by the see-saw pattern of COVID-19 vaccine effectiveness against severe disease which was similar to titers peaking in the first weeks after each dose and falling 272 thereafter until the next dose³. However, the observed larger declines in titers against Omicron 273 274 relative to the Index strain may correlate less well to clinical vaccine effectiveness against severe 275 disease, which shows less waning than VE against symptomatic disease and infection. This 276 supports that protection is aided by additional factors such as cellular immunity, which has gained increasing recognition for its importance for protection against severe disease¹⁸. While no 277 278 precise correlates of protection are defined for neutralizing antibodies, an understanding of 279 overall titers and waning rates will allow us to predict how fast protection against infection and 280 mild disease will decline and whether this might differ by vaccine type, regimen, infection history or characteristics such as sex, age, or comorbidities to inform vaccine policy, including the time 281 282 interval when additional vaccine doses should be given.

But even studying neutralization titers takes time; very few longitudinal studies with data against
Omicron subvariants other than for BA.1 were available at the time of this review, and increasing

285 immune escape from post-vaccination neutralizing antibody responses resulting in large proportions of participants with undetectable titers makes them difficult to evaluate, especially 286 in infection-naïve cohorts post-primary vaccination. Indeed, available studies for newer sub-287 variants provide contradictory results with some observing increased rates of waning against 288 289 Omicron sub-variants compared to the Index variant^{19,20}, some finding similar rates of waning²¹⁻ ²³, and others reporting lower rates^{24,25}. More evidence is needed to determine if waning of post-290 vaccination neutralizing antibody titers cross-reactive to newer Omicron subvariants differs from 291 those reactive to the Index variant or to Omicron BA.1. Such results may depend on whether the 292 293 vaccine targets the emerging subvariants. We found only one study assessing waning of neutralizing antibodies after bivalent mRNA vaccination (Index plus BA.4/5 antigen), which found 294 greater waning during the first three months against Omicron subvariants than against the Index 295 variant²⁸, similar to our observations for monovalent Index-directed vaccines. We were also 296 297 unable to assess variant-specific effects on hybrid-immunity since all hybrid-immune cohorts 298 investigated involved pre-Omicron infections.

Our results confirm observations of superior immunogenicity of some vaccination strategies over 299 others. We observed significant differences in overall titers by vaccine platform, with mRNA 300 vaccines resulting in higher titers and inactivated vaccines the lowest. Importantly, waning rates 301 302 were not significantly different between the platforms. These results support previous findings that both booster doses and hybrid-immunity significantly increase overall titers and titers 303 against Omicron BA.1 are generally lower than against the Index strain^{8,30–33}. Importantly, these 304 results provide evidence of a relatively constant rate of waning for the different groups included 305 306 in the analysis; thus, individuals immunized with a less immunogenic primary regimen are likely 307 to reach non-protective antibody titers faster. This effect becomes more significant when comparing primary regimen to hybrid-immune or boosted cohorts. These results may prove 308 informative for booster strategies, especially when vaccine supply is low or if over-immunization 309 should be avoided because of possible imprinting and a lack of variant-adapted vaccines. 310

A systematic assessment of study reliability revealed that 88% of included studies had medium, 311 312 low, or unclear reliability scores reflecting primarily poor reporting quality of study methods and details. While this does not necessarily translate to biased or unreliable data, the overall low-313 314 reliability scores and small percentage of studies with a high-reliability score reflects that data on neutralizing antibodies are difficult to compare across studies^{4,5}. This finding is further reflected 315 by the wide confidence intervals observed in our meta-regression results. However, we included 316 317 all studies meeting inclusion criteria irrespective of their reliability score for sample size reasons. 318 A sensitivity analysis did not find an association between study results and reliability score, i.e., poorer scores were not more likely to be outliers. 319

In summary, neutralizing antibody titers are an important correlate of protection against infection and continued monitoring of new vaccines as they become available and new variants as they emerge will provide important alert signals and information to help guide vaccination regimens in the future. While absolute values of neutralization titers continue to vary widely between studies, this evaluation across many cohorts provides confidence that large differences

- in waning rates after booster doses are unlikely between vaccines used widely to date. However,
- 326 significantly different baseline titers by vaccine platform and number of doses and infections
- 327 means titers will drop to non-functional levels sooner for some conditions, which is particularly 328 important for public health policymaking. Additionally, we could not evaluate the most recent
- 329 conditions, and waning against Omicron sub-variants other than BA.1 might be slightly faster.
- 330 This should be monitored carefully, as well as waning against clinically relevant Omicron sub-
- variants after variant-adapted vaccination and the impact of hybrid-immunity by Omicron sub-
- variants, especially in combination with variant-adapted vaccination.
- 333

334 <u>Contributors</u>

HJ and IS performed the systematic literature review, screened, and excluded studies. HJ, MK, RN and IS abstracted data from included studies. HJ and IS calculated GMT, SD, SE, and 95% CI from raw data where necessary. MDK performed the meta-analysis. HJ performed initial interpretation and wrote the manuscript. HJ and MK prepared figures. IS, VCJ, DRF, MDK, RN and MH reviewed the manuscript and supported interpretation. MH acquired funding. All authors read and revised the manuscript.

341

342 Acknowledgment

We thank William Dowling and Daniel Feikin for excellent discussion and for their input on interpreting the data. We thank the Peter und Traudl Engelhorn Foundation for providing a postdoctoral scholarship to H.J.

346

347 Funding

This project was funded by the Coalition for Epidemic Preparedness Innovations, grant number 138587.

350

351 **Declaration of Interest**

MMH and MDK report research grants from Pfizer (all paid to the institution) for unrelated projects. All other authors declare no competing interests.

354

355

357 **References**

- 1. Higdon, M. M. *et al.* Duration of effectiveness of vaccination against COVID-19 caused by the
- 359 omicron variant. *Lancet Infect Dis* **22**, 1114–1116 (2022).
- 2. Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid
- 361 immunity against the omicron variant and severe disease: a systematic review and meta-
- 362 regression. Lancet Infect Dis S1473-3099(22)00801–5 (2023) doi:10.1016/S1473-

363 3099(22)00801-5.

- 364 3. Feikin, D. R. *et al.* Assessing COVID-19 vaccine effectiveness against Omicron subvariants:
- Report from a meeting of the World Health Organization. *Vaccine* **41**, 2329–2338 (2023).
- 4. Jacobsen, H. *et al.* Post-Vaccination Neutralization Responses to Omicron Sub-Variants.
- 367 *Vaccines (Basel)* **10**, 1757 (2022).
- 368 5. Jacobsen, H. *et al.* Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use
- 369 Post-Vaccination Sera. *Vaccines (Basel)* **10**, 850 (2022).
- 370 6. Wilhelm, A. et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and
- 371 BA.2 by convalescent and vaccine serum and monoclonal antibodies. *eBioMedicine* 82,

372 (2022).

- 373 7. Sitaras, I. *et al.* Systematic review of primary and booster COVID-19 sera neutralizing ability
- against SARS-CoV-2 omicron variant. *NPJ Vaccines* **7**, 147 (2022).
- 8. Walls, A. C. *et al.* SARS-CoV-2 breakthrough infections elicit potent, broad, and durable
- neutralizing antibody responses. *Cell* **185**, 872-880.e3 (2022).

- 9. Jin, L. *et al.* Antibody Persistence and Safety through 6 Months after Heterologous Orally
- 378 Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously.
- 379 2022.07.26.22278072 Preprint at https://doi.org/10.1101/2022.07.26.22278072 (2022).
- 380 10. Zhang, Y. et al. Immunogenicity, durability, and safety of an mRNA and three platform-
- 381 based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A
- randomised, double-blinded, placebo-controlled, phase 2 trial. *eClinicalMedicine* **54**, (2022).
- 11. Wang, X.-J. et al. Neutralization sensitivity, fusogenicity, and infectivity of Omicron
- subvariants. *Genome Medicine* **14**, 146 (2022).
- 12. Lyke, K. E. *et al.* Rapid decline in vaccine-boosted neutralizing antibodies against SARS-
- 386 CoV-2 Omicron variant. *Cell Reports Medicine* **3**, 100679 (2022).
- 13. Behrens, G. M. N. et al. BNT162b2-boosted immune responses six months after
- 388 heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19.
- 389 *Nat Commun* **13**, 4872 (2022).
- 14. Ferreira, I. A. T. M. et al. Atypical B cells and impaired SARS-CoV-2 neutralisation
- following booster vaccination in the elderly. 2022.10.13.22281024 Preprint at
- 392 https://doi.org/10.1101/2022.10.13.22281024 (2022).
- 15. Madhi, S. A. et al. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid
- humoral immunity against variants including omicron BA.1 and BA.4 6 months after
- 395 vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial. *The Lancet*
- 396 Infectious Diseases **23**, 295–306 (2023).
- 16. Abdullahi, A. et al. SARS-COV-2 antibody responses to AZD1222 vaccination in West
- 398 Africa. *Nat Commun* **13**, 6131 (2022).

- 399 17. Shete, A. M. et al. Waning natural and vaccine-induced immunity leading to reinfection
- with SARS-CoV-2 Omicron variant. *Human Vaccines & Immunotherapeutics* 18, 2127289
 (2022).
- 402 18. Sun, P. et al. Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron
- 403 Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. *The*
- 404 *Journal of Infectious Diseases* jiad054 (2023) doi:10.1093/infdis/jiad054.
- 405 19. Cowling, B. J. *et al.* Slow Waning of Antibodies Following BNT162b2 as a Third Dose in
- 406 Adults Who Had Previously Received 2 Doses of Inactivated Vaccine. *The Journal of Infectious*
- 407 *Diseases* **227**, 251–255 (2023).
- 408 20. Kimura, I. *et al.* Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants,
 409 including BA.4 and BA.5. *Cell* 185, 3992-4007.e16 (2022).
- 410 21. Arunachalam, P. S. et al. Durability of immune responses to the booster mRNA
- 411 vaccination against COVID-19. *J Clin Invest* (2023) doi:10.1172/JCI167955.
- 412 22. Qu, P. et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4,
- and BA.5 Subvariants. *New England Journal of Medicine* **387**, 1329–1331 (2022).
- 414 23. Cheung, A. K. L. *et al.* Consistent neutralization of circulating omicron sub-variants by
- 415 hybrid immunity up to 6 months after booster vaccination. Journal of Medical Virology **95**,
- 416 e28694 (2023).
- 417 24. Itamochi, M. et al. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster
- dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. *Vaccine* **41**, 2234–2242
- 419 (2023).

- 420 25. Nair, M. S. et al. Changes in serum-neutralizing antibody potency and breadth post-
- 421 SARS-CoV-2 mRNA vaccine boost. *iScience* **26**, (2023).
- 422 26. Canetti, M. et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273
- 423 COVID-19 vaccine doses; three months follow-up. *Nat Commun* **13**, 7711 (2022).
- 424 27. Nugent, C. et al. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-
- 425 specific neutralizing activity in both nursing home residents and health care workers.
- 426 *medRxiv* 2023.01.22.23284881 (2023) doi:10.1101/2023.01.22.23284881.
- 427 28. Lasrado, N. et al. Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters.
- 428 *bioRxiv* 2023.01.22.525079 (2023) doi:10.1101/2023.01.22.525079.
- 429 29. Jacobsen, H. et al. Diminished neutralization responses towards SARS-CoV-2 Omicron
- 430 VoC after mRNA or vector-based COVID-19 vaccinations. 2021.12.21.21267898 Preprint at
- 431 https://doi.org/10.1101/2021.12.21.21267898 (2022).
- 432 30. Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by
- 433 vaccine-elicited and therapeutic antibodies. *eBioMedicine* **78**, 103944 (2022).
- 434 31. Zheng, H. *et al.* Disease profile and plasma neutralizing activity of post-vaccination
- 435 Omicron BA.1 infection in Tianjin, China: a retrospective study. *Cell Res* **32**, 781–784 (2022).
- 436 32. Edara, V.-V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing
- 437 activity against the SARS-CoV-2 omicron variant. *Cell Reports Medicine* **3**, 100529 (2022).
- 438 33. Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing
- 439 immunity against SARS-CoV-2 Omicron variant. *Cell* **185**, 457-466.e4 (2022).
- 440
- 441

442 Supplements

443 Supplementary appendix 1: Study characteristics and data from included studies

444

445 Supplementary appendix 2: Reliability assessment, individual assessment outcomes

446

447 <u>Supplementary figure 1: Reliability assessment, summary</u>

448


Author	Journal	max. impact:	Sample size	SARS-CoV-2 infection	Vaccination regimen	Sample collection period	O Demographic characterization	Olinical characterization	Protocol	 Live virus (if applicable) 	Pseudo virus (if applicable)	 Assay standardization 	O Data	Final reliability	S low risk categories [%]		
Constitution															91		
Gruell et al.	Nature medicine														100	Reliability	
Jacobsen et al.	Scientific Reports														73	Reliability	Very high
Tada et al.	Lancet e BioMedicine														91		High
Lyke et al.	Cell Reports Medicine														64		Medium
Walls et al.	Cell														82		Low
Xia et al.	Cell Host & Microbe														73		Unclear
Lapa et al.	Vaccines														82		Unclear
Pajon et al.	NEJM														82		
Abdullahi et al.	Nature Communications														82		
Singanallur et al.	Frontiers im Immunology Nature														91		
Mueksch et al.															73		
Evans et al.	Science Translational Medicine Lancet eBiomedicine														73		
Canaday et al.	Journal of Infectious Diseases														73		
Cowling et al. Behrens et al.	Nature Communications														82		
Jin et al.	medRxiv														82		
	Lancet e BioMedicine														73		
Zhang et al. Kimura et al.	Cell														82		
Ferreira et al.	medRxiv														82		
Madhi et al.	Lancet Infectious Diseases														82		
Jäger et al.	Journal of Infectious Diseases														82		
Qu et al.	NEJM														73		
Arunachalam et al.	medRxiv														100		
Wang et al.	BMC Genome Medicine														100		
Nugent et al.	medRxiv														64		
Habermann et al.	RMD Open														100		
Shete et al.	Human Vaccines and Immunotherapeutics														55		

Supplementary Figure 1: Reliability assessment. All studies that were included in the meta-analyses were assessed with a reliability score using a previously published tool⁵. Studies were considered to have high reliability if no criterion had more than a low risk score (yellow), medium reliability if no criterion was above a medium risk score (orange) and low if at least one criterion met a high risk score (red). No study met the "very high" reliability score

(no criterion with risk of bias). Studies with at least one criterion that could not be assessed (e.g. no data provided or unclear), received an unclear reliability (purple). Eleven categories are assessed by the tool and assigned an independent risk score. The maximum impact a category can have is shown as "max impact" indicating the worst possible outcome for this category. The percentage of categories with a low or no risk is shown on the right, complementing the final reliability.

459

460 Supplementary figure 2: Reliability assessment, sensitivity analysis



461

